The alteration of CBP and p300 activity is linked to the onset and development of different cancer types, including lymphomas.[7e−j] Specifically, the development of DLBCL is supported by both the lysine acetyltransferase domain‐deficient p300 as well as a catalytically active CBP.[7, 21] This is an example of how both the catalytic and scaffolding functions trigger and support the oncogenic transformation. Here, EP300 is linked to cancer.